Evicenter
MarkdownMedical informationP&T meetings
Vonaprument (ANX007)

Geographic atrophy secondary to age-related macular degeneration

Launch
Not announced
Last updated
167 sources

Executive summary

Burden of Geographic atrophy secondary to age-related macular degeneration

4 evidence topics · 28 sources

Summary: definition, epidemiology, and natural history

Geographic atrophy (GA) is “the advanced form of non-neovascular AMD”, characterized by “confluent atrophy of photoreceptors, RPE and choriocapillaris” and associated with scotoma. Loss of visual function from GA “is considered irreversible and usually bilateral”, with half of patients developing GA in both eyes within 7 years of the initial diagnosis. The most important risk factors for GA are increasing age and family history; cigarette smoking is the modifiable risk factor most consistently identified for advanced AMD, and the estimated heritability of late-stage AMD is approximately 71%.

Published studies estimate that approximately 1 million people in the United States have GA in at least 1 eye. In a claims analysis with denominators of 2,175,803 (2018) to 2,905,366 (2021) patients, the annual prevalence of GA was 0.56% in 2018, 0.55% in 2019, 0.48% in 2020, and 0.51% in 2021. Prevalence was 0.95% to 1.11% among individuals aged 75 years and older and 0.15% to 0.18% among those younger than 75 years, and 0.61% to 0.71% among individuals classified as White race and 0.09% to 0.11% among those classified as Black race. Adding 12 months to the ascertainment window raised annual prevalence to 0.85% (2018), 0.83% (2019), 0.77% (2020), and 0.74% (2021), and the authors state that the lower prevalence in claims data relative to other studies “warrants careful consideration”. Annual incidence of GA in American White adults aged 50 years and older, estimated from prevalence, was 1.9 per 1000, corresponding to approximately 160 000 new cases per year (95% credible interval 107 000 to 234 000); the rate was 4.3 per 1000 at age 65 years and older and 10.9 per 1000 at age 80 years and older.

In a pooled analysis of 39 studies, the 8 studies that reported GA and neovascular subtypes gave an overall GA prevalence of 0.44% (95% credible interval 0.15% to 1.36%), which was higher in Europeans (1.11%) than in Africans (0.14%), Asians (0.21%), and Hispanics (0.16%). An estimated 166 307 individuals in Nordic countries had GA in 2023, a number projected to reach 277 893 in 2050.

GA lesions enlarge over time. The pooled mean growth rate was 1.66 mm2/year across 23 studies (3,078 patients), and larger baseline lesions were associated with faster growth. In one cohort, the median time from any GA diagnosis to central GA was 2.5 years, and visual acuity decreased by 3.7 letters at first documentation of central GA and by 22 letters at year 5; the median time to bilateral GA was 7 years. In another cohort, 32% of eyes with noncentral GA progressed to central GA by 2 years and 57% by 4 years, best-corrected visual acuity (BCVA) declined by 2.3 letters per year overall, and the 4-year risk of subsequent neovascular AMD in eyes with incident GA was 29%. In the Proxima A study of participants with bilateral GA, the adjusted mean change in study eye BCVA from baseline to 24 months was −13.88 letters. In claims data, 479 of 4,781 individuals (10.2%) with GA without subfoveal involvement at index progressed to GA with subfoveal involvement during 12 months of follow-up. Among participants with GA followed for a median of 6.8 years, those with total GA area in the highest quartile had a higher adjusted risk of all-cause mortality than those in the lowest quartile (hazard ratio [HR] 3.42; 95% CI 1.32 to 8.86).

Summary: humanistic burden and long-term morbidity

GA can produce “dense, irreversible scotomas in the visual field” and deficits in reading, night vision, and dark adaptation, while the initial decline in visual acuity “may be relatively minor if the fovea is spared”. In one study, half of eyes with GA had maximum reading rates below 100 words per minute. In a study in the United Kingdom, Germany, Ireland, and Canada, the mean NEI VFQ-25 composite score was 53.1 points in 137 patients with GA and 84.5 points in 52 patients without GA (adjusted difference −28.82; P<0.001). In that study, 18% of patients with GA were registered as legally blind or going through the assessment process for registration, and 27.6% of patients with GA were currently driving compared with 69.2% of patients without GA. In a survey of patients with GA, nearly 86% (n = 88) did not currently drive, 67% and 68% reported moderate to extreme difficulty reading a newspaper and small print, respectively, 56% named losing their independence as their biggest concern, and 51% worried about their eyesight most or all the time. Charles Bonnet syndrome was present in 25 of 120 patients with GA (20.8%). Among 153 participants with treatment-naive GA at 9 UK National Health Service centers, median EQ-5D health index scores were 0.75 (27 participants) and 0.74 (126 participants) in the groups that rated intravitreal injections unacceptable and acceptable, respectively.

GA is responsible for approximately 20% of legal blindness in the United States. In claims data, irreversible blindness developed in 173 individuals (3.6%) with GA without subfoveal involvement, 312 (6.6%) with subfoveal involvement, and 51 (0.5%) without GA (HR 6.77 for GA without and 12.59 for GA with subfoveal involvement). In one cohort, 71.1% of patients had visual acuity in the better-seeing eye that would have made them ineligible to drive at first record of GA; over time, 16% became legally blind (median time to outcome, 6.2 years) and 66.7% became ineligible to drive (median time to outcome, 1.6 years). Across the Clinformatics, MarketScan, and PharMetrics databases, patients with GA had higher risks than controls of falls (RR 1.16 to 1.36) and fractures (RR 1.17 to 1.29) in the 4 years after the index date, and of nursing home or assisted living admissions (RR 1.06 to 1.28). In a matched claims cohort, the incidence of new-onset depression was 86.6 per 1,000 person-years with GA and 77.3 per 1,000 person-years without GA (P = 0.004), and approximately 20% of patients with GA had evidence of an anxiety disorder during follow-up.

Summary: economic burden and healthcare resource utilization

In a cost study of 18,119 patients with GA only, 2,285 with GA and visual impairment, 1,716 with GA and blindness, and 72,476 patients without GA (costs in 2021 US dollars), annual all-cause total healthcare costs were $26,696 for patients with GA only and $25,524 for patients without GA, a difference of $1,171 (95% CI 204 to 2,138; P=0.018) driven primarily by outpatient visit costs. Patients with GA and visual impairment spent an average of $5,096 more per year, and patients with GA and blindness $9,952 more per year, than patients with GA only. In that study, patients with GA had higher rates of all-cause hospitalizations (RR 1.08) and outpatient visits (RR 1.08) than patients without GA. Across the Clinformatics, MarketScan, and PharMetrics databases, patients with GA had higher risks than controls of hospitalization (RR 1.18 to 1.27) and emergency department visits (RR 1.18 to 1.21). A matched claims cohort found no statistically significant difference in inpatient stays or emergency department visits, and a higher number of outpatient visits with GA (mean 18.3 vs 16.7). In a study of 28,773 GA cases, disease-specific costs ranged from $56 to $110. In closed-claims cohorts of 5827 patients, visual acuity impairment was associated with an increase of more than 26% in total cost of care by year 2; among the severity categories, the adjusted cost ratio reached statistical significance for moderate impairment alone (1.37; 95% CI 1.00 to 1.86; P = .045).

A systematic review reported a mean total first-year cost after diagnosis of US $11,672 per patient with GA to the health-care system and a mean cost to the patient of $2863 (2020 USD) in a US retrospective study of 14,421 patients, and identified only 7 studies of GA resource use and costs. A cost-of-illness model for the United States estimated a total annual cost of €39 251 per person with GA, comprising direct medical costs of €327 (0.8%), indirect medical costs of €12 744 (32.5%), well-being costs of €11 948 (30.4%), and productivity costs of €14 232 (36.3%); the authors attribute the lower direct medical costs for GA than for neovascular AMD to the absence of GA treatment options at the time of the research, and note that the patient survey samples were relatively small. In the United Kingdom, Germany, Ireland, and Canada, the annualized average direct and indirect ophthalmic cost was €2006 per patient with GA, of which diagnostic tests and procedures accounted for €1071.

Summary: burden on caregivers and families

In a survey of patients with GA and their caregivers, 83% of caregivers drove patients to their eye appointments for GA and 76% to other medical appointments, caregivers spent a median of 10 hours per week (interquartile range 5 to 25) on household tasks the patients could otherwise have performed independently, and 81% lived with the person they cared for. Forty-one percent of caregivers had a change in employment status after becoming a caregiver; of these, 50% were unable to work due to caregiving, 29% worked fewer hours, and 12% retired early. Patients and caregivers used their own money for extra lighting, eyeglasses, and reading devices, and 44% of patients and 37% of caregivers were concerned or very concerned about the effect of GA on their finances in the future. The mean Zarit Burden Interview total score was 24.8 (SD 18.7) on a scale of 0 to 88, and correlation coefficients between patient NEI VFQ-39 scores and caregiver burden ranged from −0.63 to −0.21. In the United States cost-of-illness estimate, 12% of the productivity cost of GA was attributable to the impact on caregivers. A systematic review identified “very little information” on the humanistic effect of GA on caregivers.